XGXingjun Guo

Xingjun Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xingjun Guo has a total of 89 co-authors. Here are the top co-authors by number of shared publications:

  • Renyi Qin

    Department of Biliary–Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    17 shared publications
  • Min Zhou

    11 shared publications
  • Min Wang

    Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    8 shared publications
  • Ruizhi He

    Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    7 shared publications
  • Min Wang

    Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    6 shared publications
  • Xiuhui Shi

    Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    6 shared publications

Latest Publications

  • Open Access

    Real-world retrospective cohort study of three conversion therapy regimens for unresectable locally advanced pancreatic cancer: a single-center 5-year analysis focused on conversion resection rate and survival outcomes

    by Rui-Zhi He, Min Zhou, Yong-Jun Chen, Xing-Jun Guo

    Background: Locally advanced pancreatic cancer (LAPC) is mostly unresectable at initial diagnosis. Conversion therapy has become core treatment to downstage tumors for radical resection, yet consensus on optimal first-line regimen remains lacking. This real-world study compared three mainstream conversion regimens and identified independent survival predictors to guide individualized treatment. Methods: A single-center retrospective cohort of 172 unresectable LAPC patients receiving gemcitabine plus nab-paclitaxel (AG), modified FOLFIRINOX (mFOLFIRINOX), or AG sequential chemoradiotherapy (CRT) from 2019 to 2023 was enrolled. Tumor conversion, surgical, survival and safety outcomes were analyzed. Cox regression was adopted to screen independent prognostic factors, with PResults: The overall conversion rate reached 38.4%. mFOLFIRINOX yielded the highest conversion rate (52.8%) versus AG (32.6%) and AG + CRT (33.3%). Among 66 converted patients, 87.9% achieved R0 resection, with 34.8% major pathological response (MPR). Median overall survival (OS) of converted patients reached 32.5 months, far superior to non-converted cases (12.3 months). Multivariate analysis confirmed preoperative carbohydrate antigen 19-9 (CA19-9) normalization and prognostic nutritional index (PNI) ≥41.7 as two independent favorable prognostic markers. Grade 3–4 adverse events were most frequent in the mFOLFIRINOX group (56.6%). Conclusions: For physically fit unresectable LAPC patients, mFOLFIRINOX provides superior conversion efficacy despite higher toxicity. Normalized CA19-9 and well-maintained nutritional status are reliable prognostic biomarkers. This real-world evidence supports mFOLFIRINOX as preferred first-line conversion regimen and routine monitoring of CA19-9 and nutrition during therapy.

  • HNRNPC Promotes Keloid Progression by Modulating the Stability of N6-Methyladenosine–Modified WDR77 mRNA and Expression of TGF-β and SMAD3

    by Yuanyuan Zhan, Ning Zeng, Jing Yu, Yiping Wu, Keyu Zhu, Zihui Yang, Xingjun Guo, Qi Zhang, Zeming Liu


  • Open Access

    An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer

    by Taoyuan Yin, Jingjing Wen, Simiao Xu, Lin Chen, Zhenxiong Zhang, Shutao Pan, Min Zhou, Xingjun Guo, Min Wang, Jun Gong, et al.

    Pancreatic cancer is the seventh leading cause of cancer death worldwide, which is demonstrated with remarkable resistance to radiotherapy and chemotherapy. The identification of prognosis signature and novel prognostic markers will facilitate patient stratification and an individualized precision therapy strategy. In this study, TCGA-PAAD was used to screen prognostic E3 ubiquitin ligases and establish prognostic signatures, and GEO database was used to verify the accuracy of prognostic signatures. Functional analysis, in vitro experiments and clinical cohort studies were used to analyze the function and prognostic efficacy of the target gene. An E3 ligase-based signature of 9 genes and the nomogram were developed, and the signature was proved to accurately predict the prognosis of patients with pancreatic cancer. WDR37 might be the most prognostic E3 ubiquitin ligase in pancreatic cancer, and the clinical cohort analyses suggested a tumor‐suppressive role. The results of functional analysis and in vitro experiments indicated that WDR37 may promote the degradation of TCP1 complex to inhibit tumor and improve immune cell infiltration. The E3 ligase-based signature accurately predicted the prognosis of patients with pancreatic cancer, so it can be used as a decision-making tool to guide the treatment of patients with pancreatic cancer. At the same time, WDR37, the main gene in E3PMP signature, can be used as the most prognostic E3 ubiquitin ligase in the treatment of pancreatic cancer.


  • Open Access

    Long-term quality of life between duodenum-preserving pancreatic head resection and pancreatoduodenectomy: a systematic review and meta-analysis

    by Taoyuan Yin, Jingjing Wen, Tingting Zhen, Yangwei Liao, Zhenxiong Zhang, Hongtao Zhu, Min Wang, Shutao Pan, Xingjun Guo, Hang Zhang, et al.

    Background: The authors aimed to compare the differences in quality of life (QOL) and overall survival (OS) between duodenum-preserving pancreatic head resection (DPPHR) and pancreatoduodenectomy (PD) during long-term follow-up. DPPHR and PD have been shown to be effective in alleviating symptoms and controlling malignancies, but there is ongoing debate over whether DPPHR has an advantage over PD in terms of long-term benefits. Method: The authors searched the PubMed, Cochrane, Embase, and Web of Science databases for relevant studies comparing DPPHR and PD published before 1 May 2023. This study was registered with PROSPERO. Randomised controlled trials and non-randomised studies were included. The Mantel–Haenszel model and inverse variance method were used as statistical approaches for data synthesis. Subgroup analyses were conducted to evaluate the heterogeneity of the results. The primary outcome was the global QOL score, measured using the QLQ-C30 system. Results: The authors analysed ten studies involving 976 patients (456 DPPHR and 520 PD). The global QOL score did not differ significantly between the DPPHR and PD groups [standard mean difference (SMD) 0.21, 95% CI (−0.05, 0.46), P=0.109, I 2 =70%]; however, the OS time of patients with DPPHR was significantly improved [hazard ratio 0.59, 95% CI (0.44, 0.77), PI 2 =0%]. The follow-up length may be an important source of heterogeneity. Studies with follow-up length between two to seven years showed better global QOL for DPPHR than for PD [SMD 0.43, 95% CI (0.23, 0.64), P0.05). On the symptom scale, patients in the DPPHR group had lower scores for fatigue, nausea and vomiting, loss of appetite, insomnia, and diarrhoea than those in the PD group (all P<0.05). Conclusions: There were no significant differences in global QOL scores between the two surgeries; however, DPPHR had advantages over PD in terms of safer perioperative outcomes, lower long-term symptom scores, and longer OS times. Therefore, DPPHR should be recommended over PD for the treatment of benign pancreatic diseases and low-grade malignant tumours.


  • Open Access

    Supplementary Figure 1 from Balanced Tiam1-Rac1 and RhoA Drives Proliferation and Invasion of Pancreatic Cancer Cells

    by Xingjun Guo, Min Wang, Jianxin Jiang, Chengchen Xie, Feng Peng, Xu Li, Rui Tian, Renyi Qin

    PDF file - 11375K, A. Sorting of lentivirally transduced cell cultures to highest purity based on GFP expression. B. Western blot analysis of Tiam1 protein expression. C. Real-time RT-PCR analysis of Tiam1 mRNA expression. D. Rac1 activity determined by G-LISA assays. E. Western blotting for β-catenin in the cytoplasm and nucleus of panc-1 cells after transfection with si-rac1 or si-β-catenin or stimulation with NSC23766. F. CCK-8 analysis of cell proliferation after transfection with si-rac1 or si-β-catenin or treatment with NSC23766. G. EDU analysis of cell proliferation after transfection with si-rac1 or si-β-catenin or treatment with NSC23766.

  • Open Access

    LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation

    by Min Zhou, Shutao Pan, Tingting Qin, Chunle Zhao, Taoyuan Yin, Yang Gao, Yuhui Liu, Zhenxiong Zhang, Yongkang Shi, Yu Bai, et al.

    Background: Pancreatic ductal adenocarcinoma is prone to metastasis, resulting in short survival and low quality of life. LncRNAs are pivotal orchestrators that participate in various tumor progress. The underlying role and mechanism of lncRNA FAM83H-AS1 is still unknown in PDAC progression. Methods: To address this issue, firstly, we profiled and analyzed the aberrant lncRNA expression in TCGA database and identified FAM83H-AS1 as the most effective one in promoting the migration of pancreatic cancer cells. Then, the expression levels of FAM83H-AS1 in patient’s serum, tumor tissues and PDAC cells were detected using RT-qPCR, and FAM83H-AS1 distribution in PDAC cells was determined by performing FISH and RT-qPCR. Next, a series of in vivo and in vitro functional assays were conducted to elucidate the role of FAM83H-AS1 in cell growth and metastasis in PDAC. The regulatory relationship between FAM83H-AS1 and FAM83H (the homologous gene of FAM83H-AS1) was verified by performing protein and RNA degradation assays respectively. Co-IP assays were performed to explore the potential regulatory mechanism of FAM83H to β-catenin. Rescue assays were performed to validate the regulation of the FAM83H-AS1/FAM83H/β-catenin axis in PDAC progression. Results: FAM83H-AS1 was highly expressed in the tumor tissues and serum of patients with PDAC, and was correlated with shorter survival. FAM83H-AS1 significantly promoted the proliferation, invasion and metastasis of PDAC cells, by protecting FAM83H mRNA from degradation. Importantly, FAM83H protein manifested the similar malignant functions as that of FAM83H-AS1 in PDAC cells, and could bind to β-catenin. Specifically, FAM83H could decrease the ubiquitylation of β-catenin, and accordingly activated the effector genes of Wnt/β-catenin signaling. Conclusions: Collectively, FAM83H-AS1 could promote FAM83H expression by stabilizing its mRNA, allowing FAM83H to decrease the ubiquitylation of β-catenin, thus resulted in an amplified FAM83H-AS1/FAM83H/β-catenin signal axis to promote PDAC progression. FAM83H-AS1 might be a novel prognostic and therapeutic target for combating PDAC.


  • Open Access

    Correction: LncRNA AFAP1-AS1 promotes growth and metastasis of cholangiocarcinoma cells

    by Xiuhui Shi, Hang Zhang, Min Wang, Xiaodong Xu, Yan Zhao, Ruizhi He, Min Zhang, Min Zhou, Xu Li, Feng Peng, et al.

    [This corrects the article DOI: 10.18632/oncotarget.16880.].

  • Open Access

    MiR-146b-3p regulates proliferation of pancreatic cancer cells with stem cell-like properties by targeting MAP3K10

    by Min Zhou, Yang Gao, Min Wang, Xingjun Guo, Xu Li, Feng Zhu, Simiao Xu, Renyi Qin

    Purpose: Cancer stem cells (CSCs) initiate and maintain tumorigenesis due to their unique pluripotency. However, pancreatic stem cell gene signatures are not completely revealed yet. Here, we isolated pancreatic cancer stem cells (P-CSCs) and exploited their distinct genome-wide mRNA and miRNA expression profiles using microarrays.


  • Open Access

    The patterns of antisense long non-coding RNAs regulating corresponding sense genes in human cancers

    by Min Zhou, Xingjun Guo, Min Wang, Renyi Qin

    For decades researches of genomic transcription of all kinds of species have demonstrated that the important role of Long non-coding RNAs (LncRNAs) in whole process of life entity has been more and more attached. Owing to constant developing of advanced technology, especially the emerge of next generation sequencing, researchers could explore further in the depth and breadth of LncRNAs. Given that the unique RNA loci location with its corresponding sense gene, antisense long noncoding RNAs (AS-lncRNAs), which are one of the main categories of LncRNAs classification, would have existed an identified close connection between them in a natural physiological state. This review characterizes the patterns of regulation between AS-lncRNAs and corresponding sense genes during the process of cancer progression in human, with emphases on the regular modulation ways of the potential molecular mechanism of AS-lncRNAs and the summary of underlying treatment targets in human cancers.


  • Open Access

    Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924

    by Shutao Pan, Ming Shen, Min Zhou, Xiuhui Shi, Ruizhi He, Taoyuan Yin, Min Wang, Xingjun Guo, Renyi Qin

    Dysfunction in long noncoding RNAs (lncRNAs) is reported to participate in the initiation and progression of human cancer; however, the biological functions and molecular mechanisms through which lncRNAs affect pancreatic cancer (PC) are largely unknown. Here, we report a novel lncRNA, LINC01111, that is clearly downregulated in PC tissues and plasma of PC patients and acts as a tumor suppressor. We found that the LINC01111 level was negatively correlated with the TNM stage but positively correlated with the survival of PC patients. The overexpression of LINC01111 significantly inhibited cell proliferation, the cell cycle, and cell invasion and migration in vitro, as well as tumorigenesis and metastasis in vivo. Conversely, the knockdown of LINC01111 enhanced cell proliferation, the cell cycle, and cell invasion and migration in vitro, as well as tumorigenesis and metastasis in vivo. Furthermore, we found that high expression levels of LINC01111 upregulated DUSP1 levels by sequestering miR-3924, resulting in the blockage of SAPK phosphorylation and the inactivation of the SAPK/JNK signaling pathway in PC cells and thus inhibiting PC aggressiveness. Overall, these data reveal that LINC01111 is a potential diagnostic biomarker for PC patients, and the newly identified LINC01111/miR-3924/DUSP1 axis can modulate PC initiation and development.